RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xeris Pharmaceuticals Stock

Xeris Pharmaceuticals ROCE 2024

Xeris Pharmaceuticals ROCE

6.49

Ticker

XERS

ISIN

US98422L1070

WKN

A2JPE9

In 2024, Xeris Pharmaceuticals's return on capital employed (ROCE) was 6.49, a -508.51% increase from the -1.59 ROCE in the previous year.

Xeris Pharmaceuticals Aktienanalyse

What does Xeris Pharmaceuticals do?

Xeris Pharmaceuticals Inc is a US pharmaceutical company that was founded in 2005. The company is headquartered in Chicago and is listed on the Nasdaq stock exchange. The business model of Xeris Pharmaceuticals is focused on providing patients and medical professionals with a wide range of products and services that improve patients' lives while promoting the development of effective and safe drugs. Xeris Pharmaceuticals focuses on the development of drugs made from peptides and proteins. The aim is to provide innovative drugs to patients with rare diseases or unmet therapeutic needs. Over the years, Xeris Pharmaceuticals has diversified into various sectors. One of the most important sectors is the diabetes industry. In this area, the company offers the Gvoke product family, a lightweight auto-injection method designed for adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes. The Gvoke product is intended for patients with severe hypoglycemia and provides a quick and easy way to treat life-threatening hypoglycemic episodes. Another important sector for Xeris Pharmaceuticals is the neurology industry. In this area, the company has developed an injection device called XeriSol, specifically designed for the treatment of epilepsy or neurological seizures. The active ingredient used is diazepam, which has a rapid and reliable effect on seizures. Xeris Pharmaceuticals is also involved in cancer treatment. The company has developed a pituitary hormone analog called Pasireotide, which is used to treat Cushing's disease, a rare condition caused by hormone overproduction. The drug fits well into Xeris Pharmaceuticals' business model as it is peptide-based and offers better efficacy and safety than other drugs in this area. Overall, Xeris Pharmaceuticals has a strong pipeline of drugs that offer the company great potential for future growth. The development of innovative drugs and drug combinations is an important strategy for Xeris Pharmaceuticals to help patients with rare diseases or unmet therapeutic needs. In this regard, Xeris Pharmaceuticals has also formed partnerships with other leading pharmaceutical companies such as Sanofi, Eli Lilly, and Roche. These partnerships allow the company to accelerate its drug development and offer its products in the international market. In conclusion, the success story of Xeris Pharmaceuticals shows that the company is an important player in the pharmaceutical industry and plays a crucial role in the development of innovative, safe, and effective drugs for patients with rare diseases and unmet therapeutic needs. With its wide range of products, partnerships, and strong pipeline of innovative drugs, Xeris Pharmaceuticals is a company that has great potential for successful growth in the future. Xeris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Xeris Pharmaceuticals's Return on Capital Employed (ROCE)

Xeris Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Xeris Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Xeris Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Xeris Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Xeris Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Xeris Pharmaceuticals this year?

The ROCE of Xeris Pharmaceuticals is 6.49 undefined this year.

How has the ROCE (Return on Capital Employed) of Xeris Pharmaceuticals developed compared to the previous year?

The ROCE of Xeris Pharmaceuticals has increased by -508.51% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Xeris Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Xeris Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Xeris Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Xeris Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Xeris Pharmaceuticals impact the company?

An increase in the ROCE of Xeris Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Xeris Pharmaceuticals affect the company?

A decrease in ROCE of Xeris Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Xeris Pharmaceuticals?

Some factors that can affect Xeris Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Xeris Pharmaceuticals so important for investors?

The ROCE of Xeris Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Xeris Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Xeris Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Xeris Pharmaceuticals pay?

Over the past 12 months, Xeris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xeris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xeris Pharmaceuticals?

The current dividend yield of Xeris Pharmaceuticals is .

When does Xeris Pharmaceuticals pay dividends?

Xeris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xeris Pharmaceuticals?

Xeris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xeris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xeris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xeris Pharmaceuticals from 10/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/18/2024.

When did Xeris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/18/2024.

What was the dividend of Xeris Pharmaceuticals in the year 2023?

In the year 2023, Xeris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xeris Pharmaceuticals pay out the dividend?

The dividends of Xeris Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Xeris Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Xeris Pharmaceuticals

Our stock analysis for Xeris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xeris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.